Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1991 Feb;67(784):114–139. doi: 10.1136/pgmj.67.784.114

Rheumatology.

R A Asherson 1, R Cervera 1, D P D'Cruz 1, G R Hughes 1
PMCID: PMC2398960  PMID: 2041842

Full text

PDF
114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe Y., Inada S., Torikai K. A new autoantibody in patients with rheumatoid arthritis: characterization of the anti-HaT-1 antibody system. Arthritis Rheum. 1988 Jan;31(1):135–139. doi: 10.1002/art.1780310120. [DOI] [PubMed] [Google Scholar]
  2. Aeschlimann A., de Truchis P., Kahn M. F. Scleroderma after therapy with appetite suppressants. Report on four cases. Scand J Rheumatol. 1990;19(1):87–90. doi: 10.3109/03009749009092627. [DOI] [PubMed] [Google Scholar]
  3. Alarcón-Segovia D., Abud-Mendoza C., Diaz-Jouanen E., Iglesias A., De los Reyes V., Hernández-Ortiz J. Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol. 1988 Jan;15(1):65–69. [PubMed] [Google Scholar]
  4. Alarcón-Segovia D., Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol. 1989 Apr;16(4):482–488. [PubMed] [Google Scholar]
  5. Alarcón G. S., Tracy I. C., Blackburn W. D., Jr Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989 Jun;32(6):671–676. doi: 10.1002/anr.1780320603. [DOI] [PubMed] [Google Scholar]
  6. Allen L. S., Groff G. Treatment of Felty's syndrome with low-dose oral methotrexate. Arthritis Rheum. 1986 Jul;29(7):902–905. doi: 10.1002/art.1780290713. [DOI] [PubMed] [Google Scholar]
  7. Arnett F. C., Hirsch T. J., Bias W. B., Nishikai M., Reichlin M. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol. 1981 Nov-Dec;8(6):925–930. [PubMed] [Google Scholar]
  8. Arnett F. C. The Lyme spirochete: another cause of Reiter's syndrome? Arthritis Rheum. 1989 Sep;32(9):1182–1184. doi: 10.1002/anr.1780320921. [DOI] [PubMed] [Google Scholar]
  9. Arnett F. C., Whelton J. C., Zizic T. M., Stevens M. B. Methotrexate therapy in polymyositis. Ann Rheum Dis. 1973 Nov;32(6):536–546. doi: 10.1136/ard.32.6.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Arnold M. H., O'Callaghan J., McCredie M., Beller E. M., Kelly D. E., Brooks P. M. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. Br J Rheumatol. 1990 Apr;29(2):120–125. doi: 10.1093/rheumatology/29.2.120. [DOI] [PubMed] [Google Scholar]
  11. Asherson R. A. A "primary" antiphospholipid syndrome? J Rheumatol. 1988 Dec;15(12):1742–1746. [PubMed] [Google Scholar]
  12. Asherson R. A., Derksen R. H., Harris E. N., Bouma B. N., Gharavi A. E., Kater L., Hughes G. R. Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum. 1987 May;16(4):253–259. doi: 10.1016/0049-0172(87)90003-5. [DOI] [PubMed] [Google Scholar]
  13. Asherson R. A., Harris E. N. Anticardiolipin antibodies--clinical associations. Postgrad Med J. 1986 Dec;62(734):1081–1087. doi: 10.1136/pgmj.62.734.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Asherson R. A., Higenbottam T. W., Dinh Xuan A. T., Khamashta M. A., Hughes G. R. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol. 1990 Oct;17(10):1292–1298. [PubMed] [Google Scholar]
  15. Asherson R. A., Hughes G. R. Recurrent deep vein thrombosis and Addison's disease in "primary" antiphospholipid syndrome. J Rheumatol. 1989 Mar;16(3):378–380. [PubMed] [Google Scholar]
  16. Asherson R. A., Khamashta M. A., Baguley E., Oakley C. M., Rowell N. R., Hughes G. R. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med. 1989 Dec;73(272):1103–1115. [PubMed] [Google Scholar]
  17. Asherson R. A., Khamashta M. A., Gil A., Vazquez J. J., Chan O., Baguley E., Hughes G. R. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989 Apr;86(4):391–399. doi: 10.1016/0002-9343(89)90335-5. [DOI] [PubMed] [Google Scholar]
  18. Asherson R. A., Khamashta M. A., Ordi-Ros J., Derksen R. H., Machin S. J., Barquinero J., Outt H. H., Harris E. N., Vilardell-Torres M., Hughes G. R. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989 Nov;68(6):366–374. [PubMed] [Google Scholar]
  19. Asherson R. A., Mercey D., Phillips G., Sheehan N., Gharavi A. E., Harris E. N., Hughes G. R. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987 Aug;46(8):605–611. doi: 10.1136/ard.46.8.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Asherson R. A., Merry P., Acheson J. F., Harris E. N., Hughes G. R. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. Ann Rheum Dis. 1989 May;48(5):358–361. doi: 10.1136/ard.48.5.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Axford J. S., Mackenzie L., Lydyard P. M., Hay F. C., Isenberg D. A., Roitt I. M. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet. 1987 Dec 26;2(8574):1486–1488. doi: 10.1016/s0140-6736(87)92621-3. [DOI] [PubMed] [Google Scholar]
  22. Bacon P. A., Tunn E. J. Infection and arthritis. Q J Med. 1986 Oct;61(234):897–899. [PubMed] [Google Scholar]
  23. Baguley E., Wolfe C., Hughes G. R. Dermatomyositis in HIV infection. Br J Rheumatol. 1988 Dec;27(6):493–494. doi: 10.1093/rheumatology/27.6.493-a. [DOI] [PubMed] [Google Scholar]
  24. Baguley E., Wolfe C., Hughes G. R. Dermatomyositis in HIV infection. Br J Rheumatol. 1988 Dec;27(6):493–494. doi: 10.1093/rheumatology/27.6.493-a. [DOI] [PubMed] [Google Scholar]
  25. Banerjee A. K. Enteropathy induced by non-steroidal anti-inflammatory drugs. BMJ. 1989 Jun 10;298(6687):1539–1540. doi: 10.1136/bmj.298.6687.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Banerjee S., Wei B. Y., Hillman K., Luthra H. S., David C. S. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody. J Immunol. 1988 Aug 15;141(4):1150–1154. [PubMed] [Google Scholar]
  27. Barada F. A., O'Brien W., Horwitz D. A. Defective monocyte cytotoxicity in rheumatoid arthritis: a correlation with disease activity and reversal by levamisole. Arthritis Rheum. 1982 Jan;25(1):10–16. doi: 10.1002/art.1780250102. [DOI] [PubMed] [Google Scholar]
  28. Barnett A. J., Miller M. H., Littlejohn G. O. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol. 1988 Feb;15(2):276–283. [PubMed] [Google Scholar]
  29. Bernstein R. M., Morgan S. H., Chapman J., Bunn C. C., Mathews M. B., Turner-Warwick M., Hughes G. R. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984 Jul 21;289(6438):151–152. doi: 10.1136/bmj.289.6438.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Bilazarian S. D., Taylor A. J., Brezinski D., Hochberg M. C., Guarnieri T., Provost T. T. High-grade atrioventricular heart block in an adult with systemic lupus erythematosus: the association of nuclear RNP (U1 RNP) antibodies, a case report, and review of the literature. Arthritis Rheum. 1989 Sep;32(9):1170–1174. doi: 10.1002/anr.1780320918. [DOI] [PubMed] [Google Scholar]
  31. Black C. M., McWhirter A., Harrison N. K., Kirk J. M., Laurent G. J. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol. 1989 Apr;28(2):98–103. doi: 10.1093/rheumatology/28.2.98. [DOI] [PubMed] [Google Scholar]
  32. Black C. M. Systemic sclerosis: is there a treatment yet? Ann Rheum Dis. 1990 Sep;49(9):735–737. doi: 10.1136/ard.49.9.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Boey M. L., Colaco C. B., Gharavi A. E., Elkon K. B., Loizou S., Hughes G. R. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983 Oct 8;287(6398):1021–1023. doi: 10.1136/bmj.287.6398.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Brackertz D., Vischer T. L. OM-8980 in rheumatoid arthritis: a 6-month double blind placebo controlled multicenter study. J Rheumatol. 1989 Jan;16(1):19–23. [PubMed] [Google Scholar]
  35. Buchan G., Barrett K., Fujita T., Taniguchi T., Maini R., Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol. 1988 Feb;71(2):295–301. [PMC free article] [PubMed] [Google Scholar]
  36. Buyon J. P., Swersky S. H., Fox H. E., Bierman F. Z., Winchester R. J. Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Experience in a mother with a predominance of SS-B (La) antibodies. Arthritis Rheum. 1987 Jan;30(1):44–49. doi: 10.1002/art.1780300106. [DOI] [PubMed] [Google Scholar]
  37. Cairns J. S., Curtsinger J. M., Dahl C. A., Freeman S., Alter B. J., Bach F. H. Sequence polymorphism of HLA DR beta 1 alleles relating to T-cell-recognized determinants. Nature. 1985 Sep 12;317(6033):166–168. doi: 10.1038/317166a0. [DOI] [PubMed] [Google Scholar]
  38. Calabrese L. H. The rheumatic manifestations of infection with the human immunodeficiency virus. Semin Arthritis Rheum. 1989 May;18(4):225–239. doi: 10.1016/0049-0172(89)90043-7. [DOI] [PubMed] [Google Scholar]
  39. Canoso R. T., Zon L. I., Groopman J. E. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol. 1987 Apr;65(4):495–498. doi: 10.1111/j.1365-2141.1987.tb04157.x. [DOI] [PubMed] [Google Scholar]
  40. Catoggio L. J., Bernstein R. M., Black C. M., Hughes G. R., Maddison P. J. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis. 1983 Feb;42(1):23–27. doi: 10.1136/ard.42.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Champion G. D., Cairns D. R., Bieri D., Adena M. A., Browne C. D., Cohen M. L., Day R. O., Edmonds J. P., Graham G. G., de Jager J. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol. 1988 Jan;15(1):28–34. [PubMed] [Google Scholar]
  42. Christensen M. L., Pachman L. M., Schneiderman R., Patel D. C., Friedman J. M. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986 Nov;29(11):1365–1370. doi: 10.1002/art.1780291109. [DOI] [PubMed] [Google Scholar]
  43. Clarke C. R., Dyall-Smith D. J., Mackay I. R., Emery P., Jennens I. D., Becker G. Plasma exchange in dermatomyositis/polymyositis: beneficial effects in three cases. J Clin Lab Immunol. 1988 Nov;27(3):149–152. [PubMed] [Google Scholar]
  44. Cohen A. J., Philips T. M., Kessler C. M. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Feb;104(2):175–180. doi: 10.7326/0003-4819-104-2-175. [DOI] [PubMed] [Google Scholar]
  45. Cohen B. J., Buckley M. M., Clewley J. P., Jones V. E., Puttick A. H., Jacoby R. K. Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis. 1986 Oct;45(10):832–838. doi: 10.1136/ard.45.10.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Combe B., Pope R. M., Fischbach M., Darnell B., Baron S., Talal N. Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol. 1985 Mar;59(3):520–528. [PMC free article] [PubMed] [Google Scholar]
  47. Cooper R., Fraser S. M., Sturrock R. D., Gemmell C. G. Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1432–1434. doi: 10.1136/bmj.296.6634.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Corvetta A., Della Bitta R., Gabrielli A., Spaeth P. J., Danieli G. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol. 1989 May-Jun;7(3):295–299. [PubMed] [Google Scholar]
  49. Coull B. M., Bourdette D. N., Goodnight S. H., Jr, Briley D. P., Hart R. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke. 1987 Nov-Dec;18(6):1107–1112. doi: 10.1161/01.str.18.6.1107. [DOI] [PubMed] [Google Scholar]
  50. Couret M., Combe B., Chuong V. T., Leroux J. L., Blotman F., Sany J. Rheumatoid nodulosis: report of two new cases and discussion of diagnostic criteria. J Rheumatol. 1988 Sep;15(9):1427–1430. [PubMed] [Google Scholar]
  51. Cruz M., Mejia G., Lavalle C., Cortes J. J., Reyes P. A. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon. Clin Rheumatol. 1988 Mar;7(1):80–86. doi: 10.1007/BF02284061. [DOI] [PubMed] [Google Scholar]
  52. Dalakas M. C., Pezeshkpour G. H., Gravell M., Sever J. L. Polymyositis associated with AIDS retrovirus. JAMA. 1986 Nov 7;256(17):2381–2383. [PubMed] [Google Scholar]
  53. Dalakas M. Treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol. 1989 Dec;1(4):443–449. doi: 10.1097/00002281-198901040-00005. [DOI] [PubMed] [Google Scholar]
  54. Deutscher S. L., Harley J. B., Keene J. D. Molecular analysis of the 60-kDa human Ro ribonucleoprotein. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9479–9483. doi: 10.1073/pnas.85.24.9479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Drosos A. A., Petris C. A., Petroutsos G. M., Moutsopoulos H. M. Unusual eye manifestations in systemic lupus erythematosus patients. Clin Rheumatol. 1989 Mar;8(1):49–53. doi: 10.1007/BF02031068. [DOI] [PubMed] [Google Scholar]
  56. Dunckley H., Jazwinska E. C., Gatenby P. A., Serjeantson S. W. DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma. Tissue Antigens. 1989 Mar;33(3):418–420. doi: 10.1111/j.1399-0039.1989.tb01686.x. [DOI] [PubMed] [Google Scholar]
  57. Ejstrup L. Severe dermatomyositis treated with cyclosporin A. Ann Rheum Dis. 1986 Jul;45(7):612–613. doi: 10.1136/ard.45.7.612-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Elder M. G., de Swiet M., Robertson A., Elder M. A., Flloyd E., Hawkins D. F. Low-dose aspirin in pregnancy. Lancet. 1988 Feb 20;1(8582):410–410. doi: 10.1016/s0140-6736(88)91198-1. [DOI] [PubMed] [Google Scholar]
  59. Feldman D., Hochberg M. C., Zizic T. M., Stevens M. B. Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol. 1983 Feb;10(1):85–89. [PubMed] [Google Scholar]
  60. Fiechtner J. J., Miller D. R., Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum. 1989 Feb;32(2):194–201. doi: 10.1002/anr.1780320212. [DOI] [PubMed] [Google Scholar]
  61. Forster S. M., Seifert M. H., Keat A. C., Rowe I. F., Thomas B. J., Taylor-Robinson D., Pinching A. J., Harris J. R. Inflammatory joint disease and human immunodeficiency virus infection. Br Med J (Clin Res Ed) 1988 Jun 11;296(6637):1625–1627. doi: 10.1136/bmj.296.6637.1625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Furst D. E., Clements P. J., Hillis S., Lachenbruch P. A., Miller B. L., Sterz M. G., Paulus H. E. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989 May;32(5):584–593. doi: 10.1002/anr.1780320512. [DOI] [PubMed] [Google Scholar]
  63. Furst D. E., Koehnke R., Burmeister L. F., Kohler J., Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989 Mar;16(3):313–320. [PubMed] [Google Scholar]
  64. Galli M., Comfurius P., Maassen C., Hemker H. C., de Baets M. H., van Breda-Vriesman P. J., Barbui T., Zwaal R. F., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990 Jun 30;335(8705):1544–1547. doi: 10.1016/0140-6736(90)91374-j. [DOI] [PubMed] [Google Scholar]
  65. Gawryl M. S., Chudwin D. S., Langlois P. F., Lint T. F. The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1988 Feb;31(2):188–195. doi: 10.1002/art.1780310206. [DOI] [PubMed] [Google Scholar]
  66. Giannini E. H., Brewer E. J., Jr, Kuzmina N., Shaikov A., Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Arthritis Rheum. 1990 Apr;33(4):466–476. doi: 10.1002/art.1780330402. [DOI] [PubMed] [Google Scholar]
  67. Gilkeson G., Polisson R., Sinclair H., Vogler J., Rice J., Caldwell D., Spritzer C., Martinez S. Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of magnetic resonance imaging. J Rheumatol. 1988 Sep;15(9):1361–1366. [PubMed] [Google Scholar]
  68. Goh K. L., Wang F. Thyroid disorders in systemic lupus erythematosus. Ann Rheum Dis. 1986 Jul;45(7):579–583. doi: 10.1136/ard.45.7.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Gold J. E., Haubenstock A., Zalusky R. Lupus anticoagulant and AIDS. N Engl J Med. 1986 May 8;314(19):1252–1253. doi: 10.1056/NEJM198605083141912. [DOI] [PubMed] [Google Scholar]
  70. Golding H., Robey F. A., Gates F. T., 3rd, Linder W., Beining P. R., Hoffman T., Golding B. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med. 1988 Mar 1;167(3):914–923. doi: 10.1084/jem.167.3.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Greaves M., Malia R. G., Milford Ward A., Moult J., Holt C. M., Lindsey N., Hughes P., Goodfield M., Rowell N. R. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol. 1988 Aug;27(4):281–285. doi: 10.1093/rheumatology/27.4.281. [DOI] [PubMed] [Google Scholar]
  72. Greene W. C., Leonard W. J. The human interleukin-2 receptor. Annu Rev Immunol. 1986;4:69–95. doi: 10.1146/annurev.iy.04.040186.000441. [DOI] [PubMed] [Google Scholar]
  73. Gregersen P. K., Silver J., Winchester R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987 Nov;30(11):1205–1213. doi: 10.1002/art.1780301102. [DOI] [PubMed] [Google Scholar]
  74. Gutiérrez-Rodríguez O., Starusta-Bacal P., Gutiérrez-Montes O. Treatment of refractory rheumatoid arthritis--the thalidomide experience. J Rheumatol. 1989 Feb;16(2):158–163. [PubMed] [Google Scholar]
  75. Hahn B. H., Ebling F. M. Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol. 1984 Jan;132(1):187–190. [PubMed] [Google Scholar]
  76. Halpern R., Davidson A., Lazo A., Solomon G., Lahita R., Diamond B. Familial systemic lupus erythematosus. Presence of a cross-reactive idiotype in healthy family members. J Clin Invest. 1985 Aug;76(2):731–736. doi: 10.1172/JCI112028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Harley J. B., Kaine J. L., Fox O. F., Reichlin M., Gruber B. Ro (SS-A) antibody and antigen in a patient with congenital complete heart block. Arthritis Rheum. 1985 Dec;28(12):1321–1325. doi: 10.1002/art.1780281202. [DOI] [PubMed] [Google Scholar]
  78. Harley J. B., Sestak A. L., Willis L. G., Fu S. M., Hansen J. A., Reichlin M. A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum. 1989 Jul;32(7):826–836. [PubMed] [Google Scholar]
  79. Harris E. D., Jr Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990 May 3;322(18):1277–1289. doi: 10.1056/NEJM199005033221805. [DOI] [PubMed] [Google Scholar]
  80. Harris E. N., Chan J. K., Asherson R. A., Aber V. R., Gharavi A. E., Hughes G. R. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986 Nov;146(11):2153–2156. [PubMed] [Google Scholar]
  81. Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983 Nov 26;2(8361):1211–1214. doi: 10.1016/s0140-6736(83)91267-9. [DOI] [PubMed] [Google Scholar]
  82. Hopkins P., Belmont H. M., Buyon J., Philips M., Weissmann G., Abramson S. B. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 1988 May;31(5):632–641. doi: 10.1002/art.1780310508. [DOI] [PubMed] [Google Scholar]
  83. Hopkinson N., Doherty M. NSAID-associated gastropathy--a role for misoprostol? Br J Rheumatol. 1990 Apr;29(2):133–136. doi: 10.1093/rheumatology/29.2.133. [DOI] [PubMed] [Google Scholar]
  84. Hu S. K., Mitcho Y. L., Oronsky A. L., Kerwar S. S. Studies on the effect of methotrexate on macrophage function. J Rheumatol. 1988 Feb;15(2):206–209. [PubMed] [Google Scholar]
  85. Husby G., Tsuchiya N., Schwimmbeck P. L., Keat A., Pahle J. A., Oldstone M. B., Williams R. C., Jr Cross-reactive epitope with Klebsiella pneumoniae nitrogenase in articular tissue of HLA-B27+ patients with ankylosing spondylitis. Arthritis Rheum. 1989 Apr;32(4):437–445. doi: 10.1002/anr.1780320413. [DOI] [PubMed] [Google Scholar]
  86. Huskisson E. C. Combination chemotherapy in rheumatoid arthritis. Br J Rheumatol. 1987 Aug;26(4):243–244. doi: 10.1093/rheumatology/26.4.243. [DOI] [PubMed] [Google Scholar]
  87. Ingram S. B., Goodnight S. H., Jr, Bennett R. M. An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases. Arthritis Rheum. 1987 Oct;30(10):1167–1172. doi: 10.1002/art.1780301013. [DOI] [PubMed] [Google Scholar]
  88. Isasi C., López-Martín J. A., Angeles Trujillo M., Andreu J. L., Palacio S., Mulero J. Felty's syndrome: response to low dose oral methotrexate. J Rheumatol. 1989 Jul;16(7):983–985. [PubMed] [Google Scholar]
  89. Isenberg D. A., Shoenfeld Y., Madaio M. P., Rauch J., Reichlin M., Stollar B. D., Schwartz R. S. Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet. 1984 Aug 25;2(8400):417–422. doi: 10.1016/s0140-6736(84)92904-0. [DOI] [PubMed] [Google Scholar]
  90. Isenberg D. A., Shoenfeld Y., Walport M., Mackworth-Young C., Dudeney C., Todd-Pokropek A., Brill S., Weinberger A., Pinkas J. Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum. 1985 Sep;28(9):999–1007. doi: 10.1002/art.1780280907. [DOI] [PubMed] [Google Scholar]
  91. Jabs D. A., Fine S. L., Hochberg M. C., Newman S. A., Heiner G. G., Stevens M. B. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol. 1986 Apr;104(4):558–563. doi: 10.1001/archopht.1986.01050160114025. [DOI] [PubMed] [Google Scholar]
  92. Jabs D. A., Miller N. R., Newman S. A., Johnson M. A., Stevens M. B. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol. 1986 Apr;104(4):564–568. doi: 10.1001/archopht.1986.01050160120026. [DOI] [PubMed] [Google Scholar]
  93. Jakubowski A. A., Souza L., Kelly F., Fain K., Budman D., Clarkson B., Bonilla M. A., Moore M. A., Gabrilove J. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med. 1989 Jan 5;320(1):38–42. doi: 10.1056/NEJM198901053200107. [DOI] [PubMed] [Google Scholar]
  94. Janssens X., Veys E. M., Verbruggen G., Declercq L. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol. 1988 Sep;15(9):1346–1350. [PubMed] [Google Scholar]
  95. Johnsen V., Borg G., Trang L. E., Berg E., Brodin U. Auranofin (SK&F) in early rheumatoid arthritis: results from a 24-month double-blind, placebo-controlled study. Effect on clinical and biochemical assessments. Scand J Rheumatol. 1989;18(5):251–260. doi: 10.3109/03009748909095027. [DOI] [PubMed] [Google Scholar]
  96. Jonsson H., Nived O., Sturfelt G. The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus. J Rheumatol. 1988 Mar;15(3):505–509. [PubMed] [Google Scholar]
  97. Kahaleh M. B., LeRoy E. C. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med. 1989 Mar 15;110(6):446–450. doi: 10.7326/0003-4819-110-6-446. [DOI] [PubMed] [Google Scholar]
  98. Kahan A., Gerfaux J., Kahan A., Joret A. M., Menkès C. J., Amor B. Increased proto-oncogene expression in peripheral blood T lymphocytes from patients with systemic sclerosis. Arthritis Rheum. 1989 Apr;32(4):430–436. doi: 10.1002/anr.1780320412. [DOI] [PubMed] [Google Scholar]
  99. Kallenberg C. G., Pastoor G. W., Wouda A. A., The T. H. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982 Aug;41(4):382–387. doi: 10.1136/ard.41.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Kantharia B. K., Goulding N. J., Hall N. D., Davies J., Maddison P. J., Bacon P. A., Farr M., Wojtulewski J. A., Englehart K. M., Liyanage S. P. Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Br J Rheumatol. 1989 Apr;28(2):118–123. doi: 10.1093/rheumatology/28.2.118. [DOI] [PubMed] [Google Scholar]
  101. Keane A., Woods R., Dowding V., Roden D., Barry C. Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol. 1987 Oct;26(5):346–350. doi: 10.1093/rheumatology/26.5.346. [DOI] [PubMed] [Google Scholar]
  102. Kehrl J. H., Roberts A. B., Wakefield L. M., Jakowlew S., Sporn M. B., Fauci A. S. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 1986 Dec 15;137(12):3855–3860. [PubMed] [Google Scholar]
  103. Kehrl J. H., Wakefield L. M., Roberts A. B., Jakowlew S., Alvarez-Mon M., Derynck R., Sporn M. B., Fauci A. S. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986 May 1;163(5):1037–1050. doi: 10.1084/jem.163.5.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Kelley R. E., Gilman P. B., Kovacs A. G. Cerebral ischemia in the presence of lupus anticoagulant. Arch Neurol. 1984 May;41(5):521–523. doi: 10.1001/archneur.1984.04050170067020. [DOI] [PubMed] [Google Scholar]
  105. Kelly C. A., Mooney P., Hordon L. D., Griffiths I. D. Haematuria in rheumatoid arthritis: a follow up study. Ann Rheum Dis. 1988 Dec;47(12):993–994. doi: 10.1136/ard.47.12.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Kinsella M. B., Smith E. A., Miller K. S., LeRoy E. C., Silver R. M. Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum. 1989 May;32(5):577–583. doi: 10.1002/anr.1780320511. [DOI] [PubMed] [Google Scholar]
  107. Kitridou R. C., Wittmann A. L., Quismorio F. P., Jr Chondritis in systemic lupus erythematosus: clinical and immunopathologic studies. Clin Exp Rheumatol. 1987 Oct-Dec;5(4):349–353. [PubMed] [Google Scholar]
  108. Kopelman R. G., Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med. 1988 Jan;84(1):82–88. doi: 10.1016/0002-9343(88)90012-5. [DOI] [PubMed] [Google Scholar]
  109. Korn J. H. Immunologic aspects of scleroderma. Curr Opin Rheumatol. 1989 Dec;1(4):479–484. doi: 10.1097/00002281-198901040-00011. [DOI] [PubMed] [Google Scholar]
  110. Kozlowski C. L., Johnson M. J., Gorst D. W., Willey R. F. Lung cancer, immune thrombocytopenia and the lupus inhibitor. Postgrad Med J. 1987 Sep;63(743):793–795. doi: 10.1136/pgmj.63.743.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Kremer J. M., Jubiz W., Michalek A., Rynes R. I., Bartholomew L. E., Bigaouette J., Timchalk M., Beeler D., Lininger L. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med. 1987 Apr;106(4):497–503. doi: 10.7326/0003-4819-106-4-497. [DOI] [PubMed] [Google Scholar]
  112. Kremer J. M. Methotrexate 1989--the evolving story. J Rheumatol. 1989 Mar;16(3):261–263. [PubMed] [Google Scholar]
  113. Kähäri V. M., Heino J., Vuorio T., Vuorio E. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochim Biophys Acta. 1988 Jan 18;968(1):45–50. doi: 10.1016/0167-4889(88)90042-0. [DOI] [PubMed] [Google Scholar]
  114. Lally E. V., Jimenez S. A., Kaplan S. R. Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum. 1988 Aug;18(1):1–13. doi: 10.1016/0049-0172(88)90030-3. [DOI] [PubMed] [Google Scholar]
  115. Lang J., Price A. B., Levi A. J., Burke M., Gumpel J. M., Bjarnason I. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol. 1988 May;41(5):516–526. doi: 10.1136/jcp.41.5.516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Langevitz P., Kaplinsky N., Ehrenfeld M., Pras M. Intractable RA--treatment with combined methotrexate, azathioprine and hydroxychloroquine. Br J Rheumatol. 1989 Jun;28(3):271–272. doi: 10.1093/rheumatology/28.3.271. [DOI] [PubMed] [Google Scholar]
  117. Larsen A., Petersson I., Svensson B. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis. Br J Rheumatol. 1989 Apr;28(2):124–127. doi: 10.1093/rheumatology/28.2.124. [DOI] [PubMed] [Google Scholar]
  118. Lederman H. M., Winkelstein J. A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985 May;64(3):145–156. [PubMed] [Google Scholar]
  119. Lee L. A., Coulter S., Erner S., Chu H. Cardiac immunoglobulin deposition in congenital heart block associated with maternal anti-Ro autoantibodies. Am J Med. 1987 Oct;83(4):793–796. doi: 10.1016/0002-9343(87)90918-1. [DOI] [PubMed] [Google Scholar]
  120. Lee S. H., Gregersen P. K., Shen H. H., Nunez-Roldan A., Silver J., Winchester R. J. Strong association of rheumatoid arthritis with the presence of a polymorphic Ia epitope defined by a monoclonal antibody: comparison with the allodeterminant DR4. Rheumatol Int. 1984;4 (Suppl):17–23. doi: 10.1007/BF00541274. [DOI] [PubMed] [Google Scholar]
  121. Leslie K., Blay R., Haisch C., Lodge A., Weller A., Huber S. Clinical and experimental aspects of viral myocarditis. Clin Microbiol Rev. 1989 Apr;2(2):191–203. doi: 10.1128/cmr.2.2.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Li E. K., Ho P. C. Pseudotumor cerebri in systemic lupus erythematosus. J Rheumatol. 1989 Jan;16(1):113–116. [PubMed] [Google Scholar]
  123. Litsey S. E., Noonan J. A., O'Connor W. N., Cottrill C. M., Mitchell B. Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. N Engl J Med. 1985 Jan 10;312(2):98–100. doi: 10.1056/NEJM198501103120206. [DOI] [PubMed] [Google Scholar]
  124. Lockshin M. D., Gibofsky A., Peebles C. L., Gigli I., Fotino M., Hurwitz S. Neonatal lupus erythematosus with heart block: family study of a patient with anti-SS-A and SS-B antibodies. Arthritis Rheum. 1983 Feb;26(2):210–213. doi: 10.1002/art.1780260215. [DOI] [PubMed] [Google Scholar]
  125. Mackel A. M., DeLustro F., Harper F. E., LeRoy E. C. Antibodies to collagen in scleroderma. Arthritis Rheum. 1982 May;25(5):522–531. doi: 10.1002/art.1780250505. [DOI] [PubMed] [Google Scholar]
  126. Mackworth-Young C. G., Loizou S., Walport M. J. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis. 1989 May;48(5):362–367. doi: 10.1136/ard.48.5.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Mackworth-Young C., Chan J., Harris N., Walport M., Bernstein R., Batchelor R., Hughes G., Gharavi A. High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheumatol. 1987 Aug;14(4):723–726. [PubMed] [Google Scholar]
  128. Malaise M. G., Franchimont P. Defective in vitro gamma-interferon production in rheumatoid arthritis. Arthritis Rheum. 1987 Feb;30(2):230–231. doi: 10.1002/art.1780300217. [DOI] [PubMed] [Google Scholar]
  129. Malia R. G., Greaves M., Rowlands L. M., Lawrence A. C., Hume A., Rowell N. R., Moult J., Holt C. M., Lindsey N., Hughes P. Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol. 1988 Sep;73(3):456–460. [PMC free article] [PubMed] [Google Scholar]
  130. Marks R. M., Czerniecki M., Andrews B. S., Penny R. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum. 1988 Dec;31(12):1524–1534. doi: 10.1002/art.1780311209. [DOI] [PubMed] [Google Scholar]
  131. Masi A. T. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol. 1988 Jun;15(6):894–898. [PubMed] [Google Scholar]
  132. Mathews M. B., Bernstein R. M. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature. 1983 Jul 14;304(5922):177–179. doi: 10.1038/304177a0. [DOI] [PubMed] [Google Scholar]
  133. McCarty D. J., Carrera G. F. Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. JAMA. 1982 Oct 8;248(14):1718–1723. doi: 10.1001/jama.248.14.1718. [DOI] [PubMed] [Google Scholar]
  134. McCune W. J., Bayliss G. E. Immunosuppressive drug therapy. Curr Opin Rheumatol. 1989 Jun;1(1):80–88. doi: 10.1097/00002281-198901010-00016. [DOI] [PubMed] [Google Scholar]
  135. McCune W. J., Golbus J., Zeldes W., Bohlke P., Dunne R., Fox D. A. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med. 1988 Jun 2;318(22):1423–1431. doi: 10.1056/NEJM198806023182203. [DOI] [PubMed] [Google Scholar]
  136. McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120–4124. doi: 10.1073/pnas.87.11.4120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Merryman P. F., Crapper R. M., Lee S., Gregersen P. K., Winchester R. J. Class II major histocompatibility complex gene sequences in rheumatoid arthritis. The third diversity regions of both DR beta 1 genes in two DR1, DRw10-positive individuals specify the same inferred amino acid sequence as the DR beta 1 and DR beta 2 genes of a DR4 (Dw14) haplotype. Arthritis Rheum. 1989 Mar;32(3):251–258. doi: 10.1002/anr.1780320304. [DOI] [PubMed] [Google Scholar]
  138. Miescher P. A., Favre H., Mihatsch M. J., Chatelanat F., Huang Y. P., Zubler R. The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc. 1988 Jun;20(3 Suppl 4):224–237. [PubMed] [Google Scholar]
  139. Miller F. W., Love L. A., Biswas T., McClintock P. R., Notkins A. L., Plotz P. H. Viral and host genetic factors influence encephalomyocarditis virus-induced polymyositis in adult mice. Arthritis Rheum. 1987 May;30(5):549–556. doi: 10.1002/art.1780300509. [DOI] [PubMed] [Google Scholar]
  140. Miller F. W., Moore G. F., Weintraub B. D., Steinberg A. D. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis Rheum. 1987 Oct;30(10):1124–1131. doi: 10.1002/art.1780301006. [DOI] [PubMed] [Google Scholar]
  141. Miossec P., Dinarello C. A., Ziff M. Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum. 1986 Apr;29(4):461–470. doi: 10.1002/art.1780290402. [DOI] [PubMed] [Google Scholar]
  142. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  143. Moens H. J., Ament B. J., Feltkamp B. W., van der Korst J. K. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. J Rheumatol. 1987 Dec;14(6):1115–1119. [PubMed] [Google Scholar]
  144. Montecucco C., Bestagno M., Cerino A., Caporali R., Carnevale R., Longhi M., Pedrini M. A., Astaldi-Ricotti G. C. Anti-SSB/La antibodies in Sjögren's syndrome and related autoimmune diseases. Results of a quantitative immunoassay using a highly purified antigen. Clin Exp Rheumatol. 1989 Jan-Feb;7(1):5–11. [PubMed] [Google Scholar]
  145. Morel P. A., Fathman C. G. Immunogenetics of rheumatoid arthritis. J Rheumatol. 1989 Apr;16(4):421–423. [PubMed] [Google Scholar]
  146. Morgan S. H., Bernstein R. M., Coppen J., Halnan K. E., Hughes G. R. Total body irradiation and the course of polymyositis. Arthritis Rheum. 1985 Jul;28(7):831–835. doi: 10.1002/art.1780280717. [DOI] [PubMed] [Google Scholar]
  147. NIENHUIS R. L., MANDEMA E. A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Ann Rheum Dis. 1964 Jul;23:302–305. doi: 10.1136/ard.23.4.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Naides S. J., Field E. H. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch Intern Med. 1988 Dec;148(12):2587–2589. [PubMed] [Google Scholar]
  149. Nepom G. T., Byers P., Seyfried C., Healey L. A., Wilske K. R., Stage D., Nepom B. S. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum. 1989 Jan;32(1):15–21. doi: 10.1002/anr.1780320104. [DOI] [PubMed] [Google Scholar]
  150. Nuver-Zwart I. H., van Riel P. L., van de Putte L. B., Gribnau F. W. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis. 1989 May;48(5):389–395. doi: 10.1136/ard.48.5.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Owens G. R., Medsger T. A. Systemic sclerosis secondary to occupational exposure. Am J Med. 1988 Jul;85(1):114–116. doi: 10.1016/0002-9343(88)90515-3. [DOI] [PubMed] [Google Scholar]
  152. Parekh R. B., Dwek R. A., Sutton B. J., Fernandes D. L., Leung A., Stanworth D., Rademacher T. W., Mizuochi T., Taniguchi T., Matsuta K. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985 Aug 1;316(6027):452–457. doi: 10.1038/316452a0. [DOI] [PubMed] [Google Scholar]
  153. Pierucci A., Simonetti B. M., Pecci G., Mavrikakis G., Feriozzi S., Cinotti G. A., Patrignani P., Ciabattoni G., Patrono C. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med. 1989 Feb 16;320(7):421–425. doi: 10.1056/NEJM198902163200703. [DOI] [PubMed] [Google Scholar]
  154. Pisetsky D. S., Caster S. A. Idiotypic cross-reaction between MRL monoclonal autoantibodies with different antigen specificity. Clin Immunol Immunopathol. 1984 Mar;30(3):461–468. doi: 10.1016/0090-1229(84)90031-x. [DOI] [PubMed] [Google Scholar]
  155. Plotz P. H., Dalakas M., Leff R. L., Love L. A., Miller F. W., Cronin M. E. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989 Jul 15;111(2):143–157. doi: 10.7326/0003-4819-111-2-143. [DOI] [PubMed] [Google Scholar]
  156. Pollet S., Depner T., Moore P., Olander H., Robbins D. Mesangial glomerulopathy and IgM rheumatoid factor in rheumatoid arthritis. Nephron. 1989;51(1):107–111. doi: 10.1159/000185262. [DOI] [PubMed] [Google Scholar]
  157. Proper S. A., Fenske N. A., Burnett S. M., Luria L. W. Compromised wound repair caused by perioperative use of ibuprofen. J Am Acad Dermatol. 1988 May;18(5 Pt 2):1173–1179. doi: 10.1016/s0190-9622(88)70119-x. [DOI] [PubMed] [Google Scholar]
  158. Provost T. T., Watson R., Gammon W. R., Radowsky M., Harley J. B., Reichlin M. The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. N Engl J Med. 1987 Apr 30;316(18):1135–1138. doi: 10.1056/NEJM198704303161807. [DOI] [PubMed] [Google Scholar]
  159. Reimer G., Steen V. D., Penning C. A., Medsger T. A., Jr, Tan E. M. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum. 1988 Apr;31(4):525–532. doi: 10.1002/art.1780310409. [DOI] [PubMed] [Google Scholar]
  160. Rodriguez M. A., Williams R. C., Jr Infection and rheumatic diseases. Clin Exp Rheumatol. 1989 Jan-Feb;7(1):91–97. [PubMed] [Google Scholar]
  161. Rodrigué S., Laborde H., Catoggio P. M. Systemic lupus erythematosus and thyrotoxicosis: a hitherto little recognised association. Ann Rheum Dis. 1989 May;48(5):424–427. doi: 10.1136/ard.48.5.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Roifman C. M., Schaffer F. M., Wachsmuth S. E., Murphy G., Gelfand E. W. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA. 1987 Jul 24;258(4):513–515. doi: 10.1001/jama.1987.03400040111034. [DOI] [PubMed] [Google Scholar]
  163. Roudier J., Rhodes G., Petersen J., Vaughan J. H., Carson D. A. The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis. Scand J Immunol. 1988 Apr;27(4):367–371. doi: 10.1111/j.1365-3083.1988.tb02359.x. [DOI] [PubMed] [Google Scholar]
  164. Saag M. S., Bennett J. C. The infectious etiology of chronic rheumatic diseases. Semin Arthritis Rheum. 1987 Aug;17(1):1–23. doi: 10.1016/0049-0172(87)90013-8. [DOI] [PubMed] [Google Scholar]
  165. Salazar-Páramo M., García-de la Torre I., Hernández-Vazquez L., Ortíz-Cadena A. Evidence of a new antigen-antibody system (anti-Mic-1) in patients with systemic lupus erythematosus and hyperthyroidism. J Rheumatol. 1989 Feb;16(2):175–180. [PubMed] [Google Scholar]
  166. Sansom D. M., Bidwell J. L., Maddison P. J., Campion G., Klouda P. T., Bradley B. A. HLA DQ alpha and DQ beta restriction fragment length polymorphisms associated with Felty's syndrome and DR4-positive rheumatoid arthritis. Hum Immunol. 1987 Aug;19(4):269–278. doi: 10.1016/0198-8859(87)90044-9. [DOI] [PubMed] [Google Scholar]
  167. Schmidt C., Schooneman F., Siebert P., Weber M., Dureux J. B., Streiff F., Schmitt J. Traitement de la sclérodermie généralisée par échanges plasmatiques. Etude de dix neuf cas. Ann Med Interne (Paris) 1988;139 (Suppl 1):20–22. [PubMed] [Google Scholar]
  168. Scott J. R., Rote N. S., Branch D. W. Immunologic aspects of recurrent abortion and fetal death. Obstet Gynecol. 1987 Oct;70(4):645–656. [PubMed] [Google Scholar]
  169. Segal R., Caspi D., Tishler M., Wigler I., Yaron M. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol. 1989 Jul;16(7):914–917. [PubMed] [Google Scholar]
  170. Segal R., Mozes E., Yaron M., Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989 Apr;32(4):370–377. doi: 10.1002/anr.1780320403. [DOI] [PubMed] [Google Scholar]
  171. Semble E. L., Elster A. D., Loeser R. F., Laster D. W., Challa V. R., Pisko E. J. Magnetic resonance imaging of the craniovertebral junction in rheumatoid arthritis. J Rheumatol. 1988 Sep;15(9):1367–1375. [PubMed] [Google Scholar]
  172. Sharp G. C., Irvin W. S., Tan E. M., Gould R. G., Holman H. R. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148–159. doi: 10.1016/0002-9343(72)90064-2. [DOI] [PubMed] [Google Scholar]
  173. Simon L. S. Toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 1989 Jun;1(1):68–73. doi: 10.1097/00002281-198901010-00014. [DOI] [PubMed] [Google Scholar]
  174. Singh G., Fries J. F., Spitz P., Williams C. A. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum. 1989 Jul;32(7):837–843. [PubMed] [Google Scholar]
  175. Sondag-Tschroots I. R., Aaij C., Smit J. W., Feltkamp T. E. The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis. 1979 Jun;38(3):248–251. doi: 10.1136/ard.38.3.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Stafford-Brady F. J., Urowitz M. B., Gladman D. D., Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988 Sep;31(9):1105–1110. doi: 10.1002/art.1780310904. [DOI] [PubMed] [Google Scholar]
  177. Stastny P., Ball E. J., Khan M. A., Olsen N. J., Pincus T., Gao X. HLA-DR4 and other genetic markers in rheumatoid arthritis. Br J Rheumatol. 1988;27 (Suppl 2):132–138. doi: 10.1093/rheumatology/xxvii.suppl_2.132. [DOI] [PubMed] [Google Scholar]
  178. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  179. Stein M., Davis P. HIV and arthritis--causal or casual acquaintances? J Rheumatol. 1989 Oct;16(10):1287–1290. [PubMed] [Google Scholar]
  180. Stephens H. A., Sakkas L. I., Vaughan R. W., Teitsson I., Welsh K. I., Panayi G. S. HLA-DQw7 is a disease severity marker in patients with rheumatoid arthritis. Immunogenetics. 1989;30(2):119–122. doi: 10.1007/BF02421540. [DOI] [PubMed] [Google Scholar]
  181. Tang T. T., Sedmak G. V., Siegesmund K. A., McCreadie S. R. Chronic myopathy associated with coxsackievirus type A9. A combined electron microscopical and viral isolation study. N Engl J Med. 1975 Mar 20;292(12):608–611. doi: 10.1056/NEJM197503202921203. [DOI] [PubMed] [Google Scholar]
  182. Targoff I. N. Immunologic aspects of myositis. Curr Opin Rheumatol. 1989 Dec;1(4):432–442. doi: 10.1097/00002281-198901040-00004. [DOI] [PubMed] [Google Scholar]
  183. Taylor P. V., Scott J. S., Gerlis L. M., Esscher E., Scott O. Maternal antibodies against fetal cardiac antigens in congenital complete heart block. N Engl J Med. 1986 Sep 11;315(11):667–672. doi: 10.1056/NEJM198609113151103. [DOI] [PubMed] [Google Scholar]
  184. Vaarala O., Palosuo T., Kleemola M., Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986 Oct;41(1):8–15. doi: 10.1016/0090-1229(86)90046-2. [DOI] [PubMed] [Google Scholar]
  185. Warmold A., van den Wall Bake L., Peeters A. J., van der Ark A., Daha M. R., Cats A., van Es L. A. Immunoglobulin synthesis by peripheral blood lymphocytes in patients with ankylosing spondylitis. J Rheumatol. 1988 Sep;15(9):1410–1414. [PubMed] [Google Scholar]
  186. Waterworth R. F. The use of sulphasalazine and azathioprine in combination to treat rheumatoid arthritis. Br J Rheumatol. 1989 Oct;28(5):456–456. [PubMed] [Google Scholar]
  187. Watson R. M., Lane A. T., Barnett N. K., Bias W. B., Arnett F. C., Provost T. T. Neonatal lupus erythematosus. A clinical, serological and immunogenetic study with review of the literature. Medicine (Baltimore) 1984 Nov;63(6):362–378. [PubMed] [Google Scholar]
  188. Weetman A. P., Walport M. J. The association of autoimmune thyroiditis with systemic lupus erythematosus. Br J Rheumatol. 1987 Oct;26(5):359–361. doi: 10.1093/rheumatology/26.5.359. [DOI] [PubMed] [Google Scholar]
  189. Weinblatt M. E., Fraser P. A., Anderson R., Coblyn J. S., Trentham D. E. Diminution of the T8 subset by amiprilose hydrochloride in refractory RA. J Rheumatol. 1987 Aug;14(4):859–860. [PubMed] [Google Scholar]
  190. Wernick R., Smith D. L. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum. 1989 Jun;32(6):770–775. doi: 10.1002/anr.1780320616. [DOI] [PubMed] [Google Scholar]
  191. West S. G., Johnson S. C. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1988 May;108(5):703–706. doi: 10.7326/0003-4819-108-5-703. [DOI] [PubMed] [Google Scholar]
  192. Westgeest A. A., Boerbooms A. M., Jongmans M., Vandenbroucke J. P., Vierwinden G., van de Putte L. B. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol. 1987 Oct;14(5):893–897. [PubMed] [Google Scholar]
  193. Weyand C. M., Goronzy J. J. Immune responses to Borrelia burgdorferi in patients with reactive arthritis. Arthritis Rheum. 1989 Sep;32(9):1057–1064. doi: 10.1002/anr.1780320902. [DOI] [PubMed] [Google Scholar]
  194. Whisnant J. K., Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. Ann Rheum Dis. 1982;41 (Suppl 1):44–47. doi: 10.1136/ard.41.suppl_1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  195. White D. G., Woolf A. D., Mortimer P. P., Cohen B. J., Blake D. R., Bacon P. A. Human parvovirus arthropathy. Lancet. 1985 Feb 23;1(8426):419–421. doi: 10.1016/s0140-6736(85)91145-6. [DOI] [PubMed] [Google Scholar]
  196. Wiley C. A., Nerenberg M., Cros D., Soto-Aguilar M. C. HTLV-I polymyositis in a patient also infected with the human immunodeficiency virus. N Engl J Med. 1989 Apr 13;320(15):992–995. doi: 10.1056/NEJM198904133201507. [DOI] [PubMed] [Google Scholar]
  197. Winchester R., Bernstein D. H., Fischer H. D., Enlow R., Solomon G. The co-occurrence of Reiter's syndrome and acquired immunodeficiency. Ann Intern Med. 1987 Jan;106(1):19–26. doi: 10.7326/0003-4819-106-1-19. [DOI] [PubMed] [Google Scholar]
  198. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  199. Wong M. L., Highton J., Palmer D. G. Sequential nailfold capillary microscopy in scleroderma and related disorders. Ann Rheum Dis. 1988 Jan;47(1):53–61. doi: 10.1136/ard.47.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Wood D. D., Ihrie E. J., Dinarello C. A., Cohen P. L. Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum. 1983 Aug;26(8):975–983. doi: 10.1002/art.1780260806. [DOI] [PubMed] [Google Scholar]
  201. Yamagata N., Kobayashi K., Kasama T., Fukushima T., Tabata M., Yoneya I., Shikama Y., Kaga S., Hashimoto M., Yoshida K. Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis. J Rheumatol. 1988 Nov;15(11):1623–1627. [PubMed] [Google Scholar]
  202. Yanagisawa T., Sueishi M., Nawata Y., Akimoto T., Nozaki T., Koike T., Tomioka H., Kumagai A. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica. 1983;167(1):47–51. doi: 10.1159/000249745. [DOI] [PubMed] [Google Scholar]
  203. Yap A. S., Powell E. E., Yelland C. E., Mortimer R. H., Perry-Keene D. A. Lupus anticoagulant. Ann Intern Med. 1989 Aug 1;111(3):262–263. doi: 10.7326/0003-4819-111-3-262. [DOI] [PubMed] [Google Scholar]
  204. Yocum D. E., Klippel J. H., Wilder R. L., Gerber N. L., Austin H. A., 3rd, Wahl S. M., Lesko L., Minor J. R., Preuss H. G., Yarboro C. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med. 1988 Dec 1;109(11):863–869. doi: 10.7326/0003-4819-109-11-863. [DOI] [PubMed] [Google Scholar]
  205. Yodoi J., Uchiyama T. IL-2 receptor dysfunction and adult T-cell leukemia. Immunol Rev. 1986 Aug;92:135–156. doi: 10.1111/j.1600-065x.1986.tb01498.x. [DOI] [PubMed] [Google Scholar]
  206. Youinou P., Le Goff P., Dumay A., Lelong A., Fauquert P., Jouquan J. The antiperinuclear factor. I. Clinical and serologic associations. Clin Exp Rheumatol. 1990 May-Jun;8(3):259–264. [PubMed] [Google Scholar]
  207. Young R., Towbin B., Isern R. Scleroderma and ovarian carcinoma. Br J Rheumatol. 1990 Aug;29(4):314–314. doi: 10.1093/rheumatology/29.4.314. [DOI] [PubMed] [Google Scholar]
  208. Yu D. T., Choo S. Y., Schaack T. Molecular mimicry in HLA-B27-related arthritis. Ann Intern Med. 1989 Oct 1;111(7):581–591. doi: 10.7326/0003-4819-111-7-581. [DOI] [PubMed] [Google Scholar]
  209. Zabel P., Leimenstoll G., Gross W. L. Cyclosporin for acute dermatomyositis. Lancet. 1984 Feb 11;1(8372):343–343. doi: 10.1016/s0140-6736(84)90391-x. [DOI] [PubMed] [Google Scholar]
  210. Ziff M. Rheumatoid arthritis--its present and future. J Rheumatol. 1990 Feb;17(2):127–133. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES